Creso Pharma appoints David Russell as Chief Operating Officer

Published at Apr 4, 2017, in Biotech

Leading ASX listed medical cannabis group Creso Pharma (ASX: CPH) announced on Tuesday that it had appointed highly experienced pharmaceutical and biotech industry professional David Russell as its Chief Operating Officer.

Mr Russell has more than 25 years’ experience within the pharmaceutical and biotech industry with a number of leading global companies including Roche, Actelion Pharmaceuticals, Celgene and Novogen (ASX: NRT) .

Based in Sydney, Mr Russell will be responsible for assisting Creso’s CEO, Dr Miri Halperi Wernli, with the Company’s overall business and corporate strategy. He will also be responsible for developing the Australian business and the overall commercial strategy for the Company in Australia.

It should be noted here that Creso is still in its early stages and investors should seek professional financial advice if considering this stock for their portfolio.

Mr Russell has been responsible for building, leading and growing commercial teams resulting in multiple product launches in China, Australia and Asia in therapeutic areas covering haematology, oncology, immunology, cardiology and pulmonary medicine.

Mr Russell was also a Global Brand Leader for Swiss based biopharmaceutical company, Actelion Pharmaceuticals where he was responsible for its expansion into Asia and China.

In the past three years, Mr Russell has completed multiple projects for multinational clients including market entry strategies, product launches and distribution and logistics contracts.

Mr Russell said: “I’m excited to be joining Creso at this groundbreaking time for the medical cannabis industry. Creso is in a strong strategic position to ensure patients and consumers can benefit from the improving regulatory environment.”

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Longhou Capital Markets Pty Ltd (AFSL No. 292464). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Facebook
Twitter
Google Plus
LinkedIn